×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 4: Cardio-Oncology - Regulatory and Scientific Updates
Session Chair(s)
Zhe Jin, MD, PhD
Safety Physician, Manager, Japan Safety & Surveillance Div, R&D
Janssen Pharmaceutical K.K., Japan
Boaz Mendzelevski, MD
Consultant Cardiologist
Cardiac Safety Consultants Ltd., United Kingdom
Speaker(s)
Evaluation of Effects of Drug on QT/QTc Interval in Oncology Drug Development in Japan
Misaki Naota, DVM
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Reviewer, Office of New Drug V
Why is Cardio-oncology Important for the Regulators?
Krishna Prasad, DrMed, MD, MRCP, FRCP
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Deputy Director, Innovative Medicines, HQA/Licensing
Detection of Heart Failure and Myocardial Toxicity
Yuichi Ando, MD, PhD
Nagoya University Hospital, Japan
Professor, Dept of Clinical Oncology and Chemotherapy
Impact on 'Alternative' QT Studies in New Oncology Drug Development
Boaz Mendzelevski, MD
Cardiac Safety Consultants Ltd., United Kingdom
Consultant Cardiologist
Panel Discussion
All Session Speakers, United States
Have an account?